Holen Sie sich die Stockscreener-App
125.59
0.22%
-0.28
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$125.87
Offen:
$126.13
24-Stunden-Volumen:
5.21M
Relative Volume:
0.81
Marktkapitalisierung:
$155.93B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
17.09
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-2.76%
1M Leistung:
-6.93%
6M Leistung:
+4.31%
1J Leistung:
+12.08%
1-Tages-Spanne:
$124.29
$126.50
1-Wochen-Bereich:
$121.39
$130.80
52-Wochen-Spanne:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
125.59 | 155.93B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,133.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.87 | 579.83B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.73 | 402.35B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.05 | 294.03B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.07 | 292.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Victory Capital Management Inc. Sells 109,808 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by State Street Corp - MarketBeat
Gilead (GILD) Supports Faster South Africa Access to Lenacapavir - Insider Monkey
Martingale Asset Management L P Acquires 21,153 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Rhenman & Partners Asset Management AB Buys 46,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Trillium Asset Management LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Macquarie Group Ltd. Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Banco Santander S.A. - MarketBeat
Castleark Management LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
4,220,501 Shares in Gilead Sciences, Inc. $GILD Bought by Boston Partners - MarketBeat
Long term debt to total assets ratio of Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh – BCBA:GILD.CI - TradingView
Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh Dividends – BCBA:GILD.CI - TradingView
GILD Donates Antiviral Therapy to Support Ebola Response in Ugan - GuruFocus
Gilead donates remdesivir to Uganda for Ebola outbreak response - Investing.com
Gilead donates remdesivir to Uganda for Ebola outbreak response By Investing.com - Investing.com Canada
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief - Business Wire
UniSuper Management Pty Ltd Sells 124,258 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Vaughan David Investments LLC IL Invests $33.80 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Xponance LLC Has $29.15 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Sector Gamma AS - MarketBeat
Swiss National Bank Has $417.34 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Te Ahumairangi Investment Management Ltd Sells 8,180 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Meiji Yasuda America Inc Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Nuveen LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Great Lakes Advisors LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by DJE Kapital AG - MarketBeat
Aviva PLC Acquires 59,782 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Andra AP fonden Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
SF: Rememberance Work Is Future Work: Gilead Commits $3M For Hiv/Aids Education And Preservation - SFGATE
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut - Barchart.com
Gilead Sciences Inc (GILD) Stock Up 3.6% but GF Value Says Overv - GuruFocus
Gilead (GILD) CMO Dietmar Berger converts RSUs and withholds shares for taxes - Stock Titan
Gilead (GILD) CFO exercises 2,796 RSUs and withholds 1,341 shares for taxes - Stock Titan
Gilead (NASDAQ: GILD) officer reports RSU vesting and tax withholding on Form 4 - Stock Titan
Gilead (GILD) CEO Daniel O'Day exercises RSUs and withholds shares for taxes - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership - Gilead Sciences
Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now? - Insider Monkey
Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc Stock (GILD) Moved Up by 3.48% on Jun 11: Key Drivers Unveiled - TradingKey
Johnson Wealth Management LLC Makes New $2.51 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by LPL Financial LLC - MarketBeat
Cerity Partners LLC Buys 19,673 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development - Insider Monkey
Gilead Sciences Inc (GILD) Shares Fall 3.2% -- What GF Score of 76 Tells Investors - GuruFocus
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences Inc Stock (GILD) Closed Down by 3.12% on Jun 10: What Investors Need To Know - TradingKey
Can Gilead Sciences HIV Franchise Drive Long-Term Growth? - Yahoo Finance
Motley Fool Asset Management LLC Buys 29,394 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):